Table 1 Characteristics of the identified guidelines on management of NMIBC
Guideline ID | Target disease | Development organization | Version | Country | Funding | Pages | |
|---|---|---|---|---|---|---|---|
The edition | The type | ||||||
ESMO, 2014 [8] | BC | European Society for Medical Oncology, ESMO | The second | Full version | Europe | Not reported | 9 |
NICE, 2015 [9] | BC | National Institute for Health and Care Excellence, NICE | The first | Full version; NICE version; NICE pathways; Information for the Public (IFP) | U.K. | NICE | 500 |
CUA, 2015 [10] | NMIBC | Canadian Cancer Society, CUA | The second | Full version | Canada | Not reported | 15 |
AUA/SUO, 2016 [3] | NMIBC | American Urological Association, AUA/Society of Urologic Oncology, SUO | The first | Full version | America | AUA | 45 |
JUA, 2016 [11] | BC | Japanese Urological Association, JUA | The second | Full version | Japan | JUA | 6 |
EAU, 2018 [12] | NMIBC | European Association of Urology, EAU | Updated annually | Full version; Pocket guideline; Translated version | Europe | EAU | 48 |
ICUD/SIU, 2018 [13] | NMIBC | International Consultation on Urological Diseases, ICUD/Société Internationale d’Urologie, SIU | The fifth | Full version | International | Not reported | 10 |
CRHA/CPAM, 2018 [14] | NMIBC | Chinese Research Hospital Association, CRHA/China International Exchange and Promotive Association for Medical and Health Care, CPAM | The first | Simplified version | China | The National Key Research and Development Program of China; Health and Family Planning Commission of Hubei province joint funding project | 6 |
NCCN, 2019 [15] | BC | National Comprehensive Cancer Network, NCCN | Updated every few months | Full version | America | Not reported | 103 |